2024-10-24
Tord Labuda, our CEO, presented at Redeye Neurology Event in Stockholm on October 23rd.
Read more
2024-10-23
Tord Labuda interviewed by Redeye analyst. Read more
2024-10-11
In a recent interview with BioStock - Connecting Innovation and Capital, Tord shares insights into his extensive background in… Read more
2024-06-13
Our Business Development Director, Sebastian Hansson, presented positive data from our phase 1b study with ALZ-101 to key players… Read more
2024-06-11
CEO Kristina Torfgård presented Alzinova at Aktiespararnas' event Aktiedagarna. Read more
CEO Kristina Torfgård talks about the research results for the company's emerging candidate, the way forward and the ongoing… Read more
2024-06-07
2024-06-04
2024-05-29
The team at Alzinova AB participated in this year's Alzheimer's run hosted by Alzheimerfonden. Read more
Kristina Torfgård, our CEO, comments on Alzinova’s lead candidate, ALZ-101, now in a higher dose. Read more
2024-05-23
"We will be an obvious component in Big Pharma's Alzheimer's portfolio."… Read more
2024-05-20
Did you miss last week’s presentation about Alzinova at the Redeye Investor Forum?… Read more
2024-05-13
We're gearing up for an exhilarating experience!… Read more
2024-05-06
2024-04-23
Following our in-depth analysis of data from the initial phase Ib study, our analysis revealed that our vaccine candidate… Read more
2024-04-11
As we could announce last week, all patients in the extension part (part B) of our phase 1b study,… Read more
2024-03-26
Kristina Torfgård our CEO, presented Alzinova and participated in the panel discussion at Redeye Alzheimer Event in Stockholm. Read more
2024-03-12
Last week Alzinova got the opportunity to present at Penser by Carnegie’s company day. CEO Kristina Torfgård talked about… Read more
2024-03-05
Bistock has taken note of the Year-end report for 2023 and contacted Alzinova’s CEO Kristina Torfgård and Business Development Director Sebastian… Read more
2024-02-12
Interview in BioStock with Alzinova’s CEO Kristina Torfgård and CSO Anders Sandberg on the positive results from our phase 1b study with ALZ-101. Read more
2024-02-06
Alzinovas CEO Kristina Torfgård interviewed by Alzheimerfonden regarding the latest clinical development and results from the phase 1b study… Read more
2024-02-05
Redeye has interviewed our CEO, Kristina Torfgård. They discussed the company's primary analysis of phase Ib study data with… Read more
2024-01-11
Last fall, we welcomed Kirsten Harting to Alzinova as our Chief Medical Officer. With a wealth of expertise in… Read more
2024-01-08
Our CEO Kristina Torfgård visits Penserpodden, one of Sweden's largest finance podcasts, and talks about Alzinova and our clinical development… Read more
2023-12-05
Last week, Alzinova AB shared positive topline results from the phase 1b study with our vaccine candidate ALZ-101 against… Read more
2023-12-04
We are happy to share a new interview from Alzheimerfonden with Alzinova ABs CEO, Kristina Torfgård. In the interview,… Read more
2023-12-01
CEO Kristina Torfgård and CSO Anders Sandberg commenting on the positive results. Read more
2023-11-07
Our Business Development Director Sebastian Hansson was recently interviewed in BioStock ahead of BIO-Europe about his expectations and what Alzinova hopes… Read more
2023-10-13
Kristina Torfgård, CEO, presented at Redeye Neurology Event in Stockholm on October 11th. Read more
2023-09-20
September 21, is World Alzheimer's Day, which aims to draw attention to and raise awareness about Alzheimer's disease. In… Read more
2023-09-11
Alzinova's CEO Kristina Torfgård shares her reflections on all the important progress the company has made during the year,… Read more
2023-09-05
September marks the start of World Alzheimer's awareness month. Let's take a moment to reflect on the impact of… Read more
2023-06-12
Last week, our CEO, Kristina Torfgård, and Business Development Director, Sebastian Hansson, participated in one of the major biotech… Read more
2023-06-09
We are delighted to have participated in and sponsored Alzheimerfonden and this year's Alzheimer's Run, a significant event in raising awareness… Read more
2023-05-29
Our CEO Kristina Torfgård and Business Development Director Sebastian Hansson will be at BIO 2023 in Boston 5-8th June. Read more
2023-04-24
Alzinova is currently in the subscription period for warrants of series TO3. Alzinova has already secured subscription commitments of… Read more
2023-04-20
The presentation highlighted the latest advancements in the company's groundbreaking research on Alzheimer's disease. Check it out to learn… Read more
2023-04-05
Updated analysis from Mangold Fondkommission based on the recent milestones achieved by Alzinova that further strengthens the case for the Company. … Read more
2023-04-03
Anders tells more about the new exciting data for the vaccine candidate ALZ-101 and the ADPD conference. Read more
2023-03-29
Alzinovas CEO Kristina Torfgård attended Mangold Insight Day and held an investor presentation. Read more
2023-03-23
Exciting news about the filing of a new patent application for a further developed form of its monoclonal antibody… Read more
2023-03-03
2022 was a year of many successes, with several important milestones achieved. CEO Kristina Torfgård comments the year-end report and… Read more
2023-02-10
Read why Sebastian joined the company and what his mission will be at Alzinova AB. Read more
2023-01-27
Sebastian will be responsible for the continued business development that runs parallel to the further development of the Company's… Read more
2023-01-18
Kristina Torfgård, CEO, commenting on recent exciting events for both the company and the industry in general. Read more
2023-01-13
Alzinova's CEO Kristina Torfgård was interviewed about the accelerated approval of lecanemab… Read more
2023-01-05
Anders tells more about the new exciting data for ALZ-201 antibody and the findings and conclusions as well as… Read more
2023-01-04
In the prestigious journal Alzheimer's Research & Therapy, Alzinova presents preclinical results demonstrating that the ALZ-201 antibody has specificity… Read more
2022-12-23
Alzinova's CEO Kristina Torfgård was interviewed about the latest news on the Companies vaccine candidate ALZ-101 against Alzheimer's disease. Read more
2022-12-19
Watch our CEO Kristina Torfgård, present Alzinova (in Swedish). Read more
2022-12-02
Alzinova's CSO Anders Sandberg was interviewed about the Companies monoclonal antibody ALZ-201 that is presented in a poster presentation… Read more
